These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 39144145)

  • 21. Atypical chronic inflammatory demyelinating polyradiculoneuropathy with ophthalmoplegia and anti-sulfatide IgM positivity.
    Chen L; Zhang Y; Qin N; Han R; Li Y
    J Int Med Res; 2023 Oct; 51(10):3000605231193575. PubMed ID: 37812511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of immune-mediated, dysimmune neuropathies.
    Finsterer J
    Acta Neurol Scand; 2005 Aug; 112(2):115-25. PubMed ID: 16008538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review.
    Bright RJ; Wilkinson J; Coventry BJ
    BMC Neurol; 2014 Feb; 14():26. PubMed ID: 24507546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies.
    Briani C; Visentin A
    Neurotherapeutics; 2022 Apr; 19(3):874-884. PubMed ID: 35349079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A case with Neurofascin-155 IgG antibody-associated combined central and peripheral demyelination: Successfully treated with anti-CD20 monoclonal antibody.
    Sokmen O; Demirci M; Tan E
    Clin Neurol Neurosurg; 2021 Nov; 210():106961. PubMed ID: 34624826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rituximab in chronic immune mediated neuropathies: a systematic review.
    Chaganti S; Hannaford A; Vucic S
    Neuromuscul Disord; 2022 Aug; 32(8):621-627. PubMed ID: 35672205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous Immunoglobulin Treatment Patterns and Outcomes in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A US Claims Database Analysis.
    Anderson-Smits C; Ritchey ME; Huang Z; Chavan S; Souayah N; Ay H; Layton JB
    Neurol Ther; 2023 Aug; 12(4):1119-1132. PubMed ID: 37171778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study.
    van Schaik IN; Mielke O; Bril V; van Geloven N; Hartung HP; Lewis RA; Sobue G; Lawo JP; Praus M; Durn BL; Cornblath DR; Merkies ISJ;
    Neurol Neuroimmunol Neuroinflamm; 2019 Sep; 6(5):e590. PubMed ID: 31355323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.
    Hughes RA; Gorson KC; Cros D; Griffin J; Pollard J; Vallat JM; Maurer SL; Riester K; Davar G; Dawson K; Sandrock A;
    Neurology; 2010 Feb; 74(8):651-7. PubMed ID: 20177118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy.
    Kuitwaard K; van Doorn PA
    Drugs; 2009 May; 69(8):987-1001. PubMed ID: 19496628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Childhood chronic inflammatory demyelinating polyneuroradiculopathy--three cases and a review of the literature.
    Riekhoff AG; Jadoul C; Mercelis R; Cras P; Ceulemans BP
    Eur J Paediatr Neurol; 2012 Jul; 16(4):315-31. PubMed ID: 22225859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Current Therapies and Future Approaches.
    Svačina MKR; Lehmann HC
    Curr Pharm Des; 2022; 28(11):854-862. PubMed ID: 35339172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature.
    Benedetti L; Briani C; Franciotta D; Fazio R; Paolasso I; Comi C; Luigetti M; Sabatelli M; Giannini F; Mancardi GL; Schenone A; Nobile-Orazio E; Cocito D
    J Neurol Neurosurg Psychiatry; 2011 Mar; 82(3):306-8. PubMed ID: 20639381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of patients with refractory chronic inflammatory demyelinating polyneuropathy.
    Kaplan A; Brannagan TH
    Muscle Nerve; 2017 Apr; 55(4):476-482. PubMed ID: 27463215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic biomarkers for intravenous immunoglobulin response in chronic inflammatory demyelinating polyradiculoneuropathy.
    Kuitwaard K; van Doorn PA; Bengrine T; van Rijs W; Baas F; Nagelkerke SQ; Kuijpers TW; Fokkink WR; Bunschoten C; Broers MC; Willemsen SP; Jacobs BC; Huizinga R
    Eur J Neurol; 2021 May; 28(5):1677-1683. PubMed ID: 33460483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CIDP variants in diabetes: measuring treatment response with a small nerve fiber test.
    Névoret ML; Vinik AI
    J Diabetes Complications; 2015 Mar; 29(2):313-7. PubMed ID: 25466645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [CIDP Refractory to Three Types of Mainstay Treatments: Differential Diagnosis and Treatment Strategies].
    Iijima M
    Brain Nerve; 2022 May; 74(5):517-524. PubMed ID: 35589641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic inflammatory demyelinating polyneuropathy: Plasmapheresis or cyclosporine can be good treatment options in refractory cases.
    Kim W; Shim YK; Choi SA; Kim SY; Kim H; Lim BC; Hwang H; Choi J; Kim KJ; Chae JH
    Neuromuscul Disord; 2019 Sep; 29(9):684-692. PubMed ID: 31473049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic inflammatory demyelinating polyradiculoneuropathy and variants: where we are and where we should go.
    Nobile-Orazio E
    J Peripher Nerv Syst; 2014 Mar; 19(1):2-13. PubMed ID: 24612201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies.
    Dalakas MC
    J Peripher Nerv Syst; 2012 May; 17 Suppl 2():34-9. PubMed ID: 22548621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.